Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The purpose of this research study is to determine if Telcyta® given in combination with liposomal doxorubicin is more effective than liposomal doxorubicin alone in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer that is refractory or resistant to platinum chemotherapy.
Epistemonikos ID: 4c3f96ca826219671c865fcf4ec60f9ecdc5356d
First added on: May 04, 2024